ReviewFrontiers in reproductive health2025
Recurrence rate of perianal and intra-anal genital warts treated with aminolevulinic acid photodynamic therapy: a meta-analysis.
Review in Frontiers in reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This meta-analysis and systematic review aimed to evaluate the recurrence rate and clinical efficacy of aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of perianal and intra-anal genital warts. Methods: We systematically searched the China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP, Chinese Biomedicine (CBM), PubMed, and Cochrane Library databases from their inception to April 1, 2024, for randomized controlled trials (RCTs) investigating ALA-PDT for perianal and intra-anal genital warts. Study quality was assessed using the Cochrane Collaboration's risk of bias tool, and statistical analysis was performed using RevMan 5.3 software. Results: After rigorous screening, 32 RCTs involving 2,538 patients were included. The recurrence rate of perianal and intra-anal genital warts treated with ALA-PDT was significantly lower than that in conventional treatment groups (OR = 0.17, 95% CI [0.13, 0.22], Conclusion: ALA-PDT effectively reduces recurrence rates of perianal and intra-anal genital warts and enhances treatment efficacy when used in combination with conventional therapies. As all included studies were conducted in China, further multinational RCTs are warranted to validate these findings across diverse populations. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024501535.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.